J. Kremer, Safty, efficacy, and mortality in a long-term cohort of patients with rheumatoid arthritis taking methotrexate: Folloup after a mean of 13.3 years, Arthritis & Rheumatism, vol.33, issue.5, pp.984-985, 1997.
DOI : 10.1002/art.1780400533

E. Keystone, A. Kavanaugh, J. Sharp, H. Tannenbaum, Y. Hau et al., Radiographic, clinical, and functional outcomes of treatment with adalimumab (a human anti-tumor necrosis factor monoclonal antibody) in patients with active rheumatoid arthritis receiving concomitant methotrexate therapy: A randomized, placebo-controlled, 52-week trial, Arthritis & Rheumatism, vol.46, issue.5, pp.1400-1411, 2004.
DOI : 10.1002/art.20217

F. Breedveld, M. Weisman, A. Kavanaugh, S. Cohen, K. Pavelka et al., The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment, Arthritis & Rheumatism, vol.39, issue.1, pp.26-37, 2006.
DOI : 10.1002/art.21519

E. Keystone, A. Kavanaugh, M. Weinblatt, K. Patra, and A. Pangan, Clinical Consequences of Delayed Addition of Adalimumab to Methotrexate Therapy Over 5 Years in Patients with Rheumatoid Arthritis, The Journal of Rheumatology, vol.38, issue.5, pp.855-862, 2011.
DOI : 10.3899/jrheum.100752

R. Maini, S. Clair, W. Breedveld, F. Furst, D. Kalden et al., Infliximab (chimeric anti-tumour necrosis factor ?? monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial, The Lancet, vol.354, issue.9194, pp.1932-1939, 1999.
DOI : 10.1016/S0140-6736(99)05246-0

. Weinblattme, . Kremerjm, . Bankhurstad, . Bulpittkj, . Fleischmannrm et al., A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate, pp.253-259, 1999.

M. Weinblatt, E. Keystone, D. Furst, A. Kavanaugh, E. Chartash et al., Long term efficacy and safety of adalimumab plus methotrexate in patients with rheumatoid arthritis: ARMADA 4 year extended study, Annals of the Rheumatic Diseases, vol.65, issue.6
DOI : 10.1136/ard.2005.044404

E. Keystone, D. Van-der-heijde, D. Mason, . Jr, R. Landewé et al., Certolizumab pegol plus methotrexate is significantly more effective than placebo plus methotrexate in active rheumatoid arthritis: Findings of a fifty-two-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group study, Arthritis & Rheumatism, vol.340, issue.11, pp.3319-3329, 2008.
DOI : 10.1002/art.23964

E. Keystone, M. Genovese, L. Klareskog, E. Hsia, S. Hall et al., Golimumab, a human antibody to tumour necrosis factor ?? given by monthly subcutaneous injections, in active rheumatoid arthritis despite methotrexate therapy: the GO-FORWARD Study, Annals of the Rheumatic Diseases, vol.68, issue.6, pp.789-796, 2009.
DOI : 10.1136/ard.2008.099010

J. Nam, K. Winthrop, R. Van-vollenhoven, K. Pavelka, G. Valesini et al., Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA, Annals of the Rheumatic Diseases, vol.69, issue.6
DOI : 10.1136/ard.2009.126573

G. Burmester, X. Mariette, C. Montecucco, I. Monteagudo-sáez, M. Malaise et al., Adalimumab alone and in combination with disease-modifying antirheumatic drugs for the treatment of rheumatoid arthritis in clinical practice: the Research in Active Rheumatoid Arthritis (ReAct) trial, Annals of the Rheumatic Diseases, vol.66, issue.6, pp.732-739, 2007.
DOI : 10.1136/ard.2006.066761

S. Bombardieri, A. Ruiz, P. Fardellone, P. Geusens, F. Mckenna et al., Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice, Rheumatology, vol.46, issue.7, pp.1191-1199, 2007.
DOI : 10.1093/rheumatology/kem091

D. Felson, J. Anderson, M. Boers, C. Bombardier, D. Furst et al., American college of rheumatology preliminary definition of improvement in rheumatoid arthritis, Arthritis & Rheumatism, vol.37, issue.6, pp.727-735, 1995.
DOI : 10.1002/art.1780380602

A. Van-gestel, M. Prevoo, M. Van-'t-hof, M. Van-rijswijk, L. Van-de-putte et al., Development and validation of the european league against rheumatism response criteria for rheumatoid arthritis: Comparison with the preliminary american college of rheumatology and the world health organization/international league against rheumatism criteria, Arthritis & Rheumatism, vol.38, issue.1, pp.34-40, 1996.
DOI : 10.1002/art.1780390105

D. Felson, J. Smolen, G. Wells, B. Zhang, L. Van-tuyl et al., American College of Rheumatology/European League Against Rheumatism Provisional Definition of Remission in Rheumatoid Arthritis for Clinical Trials, Annals of the Rheumatic Diseases, vol.70, issue.3, pp.404-413, 2011.
DOI : 10.1136/ard.2011.149765

J. Galloway, K. Hyrich, L. Mercer, W. Dixon, B. Fu et al., Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly, BSRBR Control Centre Consortium, Symmons DPM, pp.124-131, 2011.
DOI : 10.1093/rheumatology/keq242

A. Strangfeld, M. Eveslage, M. Schneider, H. Bergerhausen, T. Klopsch et al., Treatment benefit or survival of the fittest: what drives the timedependent decrease in serious infection rates under TNF inhibition and what does this imply for the individual patient? Ann Rheum Dis, pp.1914-1920, 2011.

A. Gibofsky, W. Palmer, E. Keystone, M. Schiff, J. Feng et al., Rheumatoid Arthritis Disease-modifying Antirheumatic Drug Intervention and Utilization Study: Safety and Etanercept Utilization Analyses from the RADIUS 1 and RADIUS 2 Registries, The Journal of Rheumatology, vol.38, issue.1, pp.21-28, 2011.
DOI : 10.3899/jrheum.100347

J. Greenberg, G. Reed, D. Decktor, L. Harrold, D. Furst et al., A comparative effectiveness study of adalimumab, etanercept and infliximab in biologically naive and switched rheumatoid arthritis patients: results from the US CORRONA registry, Annals of the Rheumatic Diseases, vol.71, issue.7, pp.1134-1142, 2012.
DOI : 10.1136/annrheumdis-2011-150573

M. Hetland, I. Christensen, U. Tarp, L. Dreyer, A. Hansen et al., Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: Results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry, Arthritis & Rheumatism, vol.64, issue.5, pp.22-32, 2010.
DOI : 10.1002/art.27227

G. Burmester, P. Mease, B. Dijkmans, K. Gordon, D. Lovell et al., Adalimumab safety and mortality rates from global clinical trials of six immune-mediated inflammatory diseases, Annals of the Rheumatic Diseases, vol.68, issue.12, pp.1863-1869, 2009.
DOI : 10.1136/ard.2008.102103

M. Schiff, G. Burmester, J. Kent, A. Pangan, H. Kupper et al., Safety analyses of adalimumab (HUMIRA) in global clinical trials and US postmarketing surveillance of patients with rheumatoid arthritis, Annals of the Rheumatic Diseases, vol.65, issue.7, pp.889-894, 2006.
DOI : 10.1136/ard.2005.043166

W. Dixon, K. Watson, M. Lunt, K. Hyrich, A. Silman et al., Rates of serious infection, including site-specific and bacterial intracellular infection, in rheumatoid arthritis patients receiving anti???tumor necrosis factor therapy: Results from the British Society for Rheumatology Biologics Register, Arthritis & Rheumatism, vol.50, issue.8, pp.2368-2376, 2006.
DOI : 10.1002/art.21978

G. Burmester, R. Panaccione, K. Gordon, M. Mcilraith, and A. Lacerda, Adalimumab: long-term safety in 23 458 patients from global clinical trials in rheumatoid arthritis, juvenile idiopathic arthritis, ankylosing spondylitis, psoriatic arthritis, psoriasis and Crohn's disease, Annals of the Rheumatic Diseases, vol.72, issue.4, pp.517-524, 2013.
DOI : 10.1136/annrheumdis-2011-201244

N. Nishimoto, N. Miyasaka, K. Yamamoto, S. Kawai, T. Takeuchi et al., Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor monoclonal antibody, in monotherapy, in patients with rheumatoid arthritis (the STREAM study): evidence of safety and efficacy in a 5-year extension study, Annals of the Rheumatic Diseases, vol.68, issue.10, pp.1580-1584, 2009.
DOI : 10.1136/ard.2008.092866

R. Westhovens, J. Kremer, L. Moreland, P. Emery, A. Russell et al., Safety and Efficacy of the Selective Costimulation Modulator Abatacept in Patients with Rheumatoid Arthritis Receiving Background Methotrexate: A 5-year Extended Phase IIB Study, The Journal of Rheumatology, vol.36, issue.4, pp.736-742, 2009.
DOI : 10.3899/jrheum.080813

E. Baecklund, A. Iliadou, J. Askling, A. Ekbom, C. Backlin et al., Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis & Rheumatism, vol.36, issue.3, pp.692-701, 2006.
DOI : 10.1002/art.21675

A. Smitten, T. Simon, M. Hochberg, and S. Suissa, A meta-analysis of the incidence of malignancy in adult patients with rheumatoid arthritis, Arthritis Research & Therapy, vol.10, issue.2
DOI : 10.1186/ar2404

J. Askling, R. Van-vollenhoven, F. Granath, P. Raaschou, C. Fored et al., Cancer risk in patients with rheumatoid arthritis treated with anti-tumor necrosis factor ?? therapies: Does the risk change with the time since start of treatment?, Arthritis & Rheumatism, vol.64, issue.11, pp.3180-3189, 2009.
DOI : 10.1002/art.24941

F. Wolfe and K. Michaud, The effect of methotrexate and anti???tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 PERSON-YEARS of observation, Arthritis & Rheumatism, vol.52, issue.5, pp.1433-1439, 2007.
DOI : 10.1002/art.22579

X. Mariette, M. Matucci-cerinic, K. Pavelka, P. Taylor, R. Van-vollenhoven et al., Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis, Annals of the Rheumatic Diseases, vol.70, issue.11
DOI : 10.1136/ard.2010.149419

G. Burmester, S. Kary, K. Unnebrink, B. Guerette, U. Oezer et al., Threeyear effectiveness of adalimumab in patients with rheumatoid arthritis with and without history of other tumor necrosis factor ? antagonist therapies, Arthritis Rheum, vol.60, p.1681, 2009.

J. Karlsson, L. Kristensen, M. Kapetanovic, A. Gülfe, T. Saxne et al., Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register, Rheumatology, vol.47, issue.4, pp.507-513, 2008.
DOI : 10.1093/rheumatology/ken034

J. Markenson, A. Gibofsky, W. Palmer, E. Keystone, M. Schiff et al., Persistence with Anti-Tumor Necrosis Factor Therapies in Patients with Rheumatoid Arthritis: Observations from the RADIUS Registry, The Journal of Rheumatology, vol.38, issue.7, pp.1273-1281, 2011.
DOI : 10.3899/jrheum.101142

E. Lie, D. Van-der-heijde, T. Uhlig, K. Mikkelsen, S. Kalstad et al., Treatment strategies in patients with rheumatoid arthritis for whom methotrexate monotherapy has failed: data from the NOR-DMARD register, Annals of the Rheumatic Diseases, vol.70, issue.12, pp.2103-2110, 2011.
DOI : 10.1136/ard.2011.152363